174 related articles for article (PubMed ID: 29507787)
1. Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma.
Sonvico F; Barbieri S; Colombo P; Mucchino C; Barocelli E; Cantoni AM; Cavazzoni A; Petronini PG; Rusca M; Carbognani P; Ampollini L
J Thorac Dis; 2018 Jan; 10(Suppl 2):S194-S206. PubMed ID: 29507787
[TBL] [Abstract][Full Text] [Related]
2. Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
Sonvico F; Barbieri S; Colombo P; Barocelli E; Mucchino C; Cantoni AM; Petronini PG; Rusca M; Carbognani P; Ampollini L
Eur J Pharm Sci; 2018 Oct; 123():89-97. PubMed ID: 30030099
[TBL] [Abstract][Full Text] [Related]
3. Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
Ampollini L; Barocelli E; Cavazzoni A; Petronini P; Mucchino C; Cantoni AM; Leonardi F; Ventura L; Barbieri S; Colombo P; Fusari A; Carbognani P; Rusca M; Sonvico F
J Thorac Dis; 2018 Jan; 10(Suppl 2):S207-S220. PubMed ID: 29507788
[TBL] [Abstract][Full Text] [Related]
4. Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study.
Ampollini L; Sonvico F; Barocelli E; Cavazzoni A; Bilancia R; Mucchino C; Cantoni AM; Carbognani P
Eur J Cardiothorac Surg; 2010 Mar; 37(3):557-65. PubMed ID: 19766508
[TBL] [Abstract][Full Text] [Related]
5. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
6. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
7. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Assessment of Cisplatin/Hyaluronan Complex for Loco-Regional Chemotherapy.
Banella S; Saraswat A; Patel A; Serajuddin ATM; Colombo P; Patel K; Colombo G
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958708
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan.
Cafaggi S; Russo E; Stefani R; Parodi B; Caviglioli G; Sillo G; Bisio A; Aiello C; Viale M
Invest New Drugs; 2011 Jun; 29(3):443-55. PubMed ID: 20039098
[TBL] [Abstract][Full Text] [Related]
11. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
[TBL] [Abstract][Full Text] [Related]
12. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
13. Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model.
Viale M; Rossi M; Russo E; Cilli M; Aprile A; Profumo A; Santi P; Fenoglio C; Cafaggi S; Rocco M
Invest New Drugs; 2015 Dec; 33(6):1151-61. PubMed ID: 26445859
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.
Denis I; Cellerin L; Gregoire M; Blanquart C
Oncotarget; 2014 Nov; 5(22):11641-52. PubMed ID: 25361002
[TBL] [Abstract][Full Text] [Related]
15. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
16. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
17. Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma - A rare thoracic cancer.
Shukla SK; Chan A; Parvathaneni V; Gupta V
Int J Biol Macromol; 2020 Oct; 160():128-141. PubMed ID: 32445818
[TBL] [Abstract][Full Text] [Related]
18. Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
Ando H; Kobayashi S; Abu Lila AS; Eldin NE; Kato C; Shimizu T; Ukawa M; Kawazoe K; Ishida T
J Control Release; 2015 Dec; 220(Pt A):29-36. PubMed ID: 26476173
[TBL] [Abstract][Full Text] [Related]
19. Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma.
Banella S; Quarta E; Colombo P; Sonvico F; Pagnoni A; Bortolotti F; Colombo G
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33803276
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
